This study shows a novel function of GAPDH in homeostatic control of the heart, which is disturbed and results in cardiac hypertrophy with pathological stressors.
which was associated with nuclear accumulation of GAPDH in cardiac myocytes isolated from TAC hearts, as detected by immunostaining ( Fig. 1B) . Nuclear GAPDH accumulation was confirmed by protein sub-cellular fractionation analysis in the heart tissues (Fig. 1C) . GAPDH in the nuclear fraction was increased in both TAC 10D and TAC 63D hearts, but not in sham hearts, while GAPDH in the cytosol fraction was unaltered under all conditions. These results are consistent with our hypothesis that TAC elicits nuclear translocation of GAPDH followed by activation of p300. PUMA was unchanged in TAC 10D hearts ( fig. S1) , indicating that the mechanism involving nuclear GAPDH in the heart is different from previously described (ref) .
To test this possibility, we needed to block the nuclear GAPDH cascade. We previously reported that deprenyl, a monoamie oxidase (MAO) inhibitor, and its structural analogue could selectively block the nuclear cascade in cells by inhibiting GAPDH-Siah1 protein interaction (14) . We performed extended screening of structural analogues of deprenyl, and identified more potent and selective blockers of GAPDH-Siah1 binding (data not shown). One of the most promising compounds was (1R, 3R)-1, 3-dimethyl-2-propargyl-1, 2, 3, 4-tetrahydroisoquinoline (designated RR in the present manuscript) ( Fig. 2A and Supplementary Information) . While deprenly's MAO inhibitory action could elicit adverse cardiovascular effects due to excess levels of catecholamine and serotonin (15, 16) , RR did not inhibit MAO-A/B at a wide range of concentrations in cardiac myocytes (Fig. 2B) . Moreover, RR did not affect GAPDH glycolytic activity in cardiac myocytes at 1 nM (Fig. 2C) , the dose used in our subsequent studies.
Comprehensive in vitro screening of off-target activities revealed no significant interaction of RR with receptors, transporters and enzymes at the concentration of 1 µM, which is 1,000 fold high in comparison to that at which GAPDH-Siah1 binding was inhibited (Table S1 ). These results support the high specificity of RR in inhibiting the GAPDH-Siah1 binding.
We tested the role of nuclear GAPDH pathway in cardiac cellular hypertrophy model induced by Gq signal stimulation, a central trigger for pathological hypertrophy response and oxidative stress (17) (18) (19) (20) (21) . Stimulation of cardiac myocytes with a Gq agonist endothelin 1 (ET1) (0.05 µM, 48h) augmented GAPDH-Siah1 binding, which was normalized by co-treatment with RR at 1 nM (Fig. 3A) . Both immunofluorescent cell staining and biochemical fractionation indicated that nuclear translocation of GAPDH occurred in response to ET1, and that RR blocked the translocation (Fig. 3, B and C, and fig. S2A ). Consistent with the ET1-elicited translocation, accumulation of sulfonated GAPDH (reflecting oxidized nuclear GAPDH (5)) was observed in the nucleus, which was also blocked by RR ( fig. S2 , B and C). Augmented p300 activity leads to the activation of cardiac hypertrophic gene program by increase in the transcriptional activity of myocyte enhancer factor 2 (MEF2) (22) (23) (24) . ET1 increased the levels of p300 acetylation (reflecting p300 HAT activity (25) ) and the activity of MEF2 (Fig. 3D) , and induced robust cellular hypertrophic response including increases in cell surface area, protein synthesis assayed by [ 3 H]leucine uptake, and B-type natriuretic peptide (BNP) expression ( Fig.   3E ). Of note, under this condition, PUMA mRNA expression was unchanged ( fig. S2D ).
Importantly, all of these changes were attenuated by RR ( Fig. 3, D and E) . These results provide pharmacological evidence that the GAPDH-p300-MEF2 cascade, which is independent of the PUMA-mediated death signaling, plays a crucial role in cardiac hypertrophic response.
To determine the significance of the nuclear GAPDH cascade in vivo and explore a novel therapeutic strategy for cardiac hypertrophy, we tested the RR compound in the pressure overload (TAC) model (see Fig. 1 ). Daily treatment with RR (0.25 mg/kg/day i.p.), initiated at the induction of TAC, markedly reduced the levels of nuclear GAPDH and p300 HAT activity in TAC 10D hearts (Fig. 3F) , and ameliorated cardiac hypertrophy remodeling in vivo, as assessed by heart weight, myocyte cell size (cell surface area of cardiac myocytes), fibrosis ( Fig. 3 , G and H) and pathological gene expression profiles ( fig. S3, A and B ). RR treatment also improved TAC-induced cardiac functional impairment (reduction in FS, fractional shortening) and chamber enlargement (increase in LV-EDD, left ventricular end-diastolic dimension), assessed by echocardiography ( Fig. 3I ). An invasive hemodynamic study using pressure volume loop analyses further revealed improvement of cardiac systolic (dPdtmax) and diastolic (Tau) performance with RR treatment despite sustained pressure-overload ( Fig. 3J and fig. S3C ).
These results indicate that the RR compound is effective in blocking the nuclear GAPDH cascade and consequent changes in cardiac hypertrophy/remodeling and function in vivo.
In most clinical settings, treatment is started only after pathological changes have occurred. Thus, we next tested the efficacy of RR treatment in pre-existing cardiac hypertrophy.
Hearts exposed to pressure-overload for 7 days (TAC 7D) developed hypertrophy with 50% increase in left ventricular (LV) mass, compared with sham controls, by echocardiography ( Fig.   3K ). Two weeks of RR treatment to TAC 7D hearts significantly inhibited further increase in LV mass, compared with vehicle treatment ( Fig. 3K and fig. S3D ), and resulted in smaller cardiac myocytes ( Fig. 3K and fig. S3D ) and improved BNP expression profile ( fig. S3D ).
We further validated this mechanism employing molecular intervention both in vitro and in vivo. The human lysine residue K227 of GAPDH is crucial for its binding to Siah1 (corresponding to mouse K225A mutant). Expression of mutant GAPDH with substitution of this lysine interferes with endogenous GAPDH binding with Siah1 to function as a dominantnegative in this cascade (5) . Thus, we first confirmed that this dominant-negative human GAPDH-K227 remained in the cytoplasm in cultured cardiac myocytes exposed to ET1 ( Fig.   4A ). Consistent with the pharmacological intervention, expression of this dominant-negative GAPDH blocked the augmentation of MEF2 activity (Fig. 4B) , and outcome measures for the cardiac hypertrophic response, including an increase in BNP expression and cell surface area ( Fig. 4C, and fig. S2E ). Next, we generated a cardiac myocyte-specific knock-in mouse harboring GAPDH K225A mutant ( Fig. 4D) , using the tamoxifen-inducible Cre-loxP system, and examined the hypertrophic response of the heart to pressure overload (TAC). K225A mutant hearts revealed virtually abrogated GAPDH-Siah1 binding after exposure to10-day TAC ( Fig.4E ). Importantly, this was associated with ameliorated cardiac function, as assessed by echocardiographic measures of FS ( Fig. 4F) , indicating the response of K225A mutants as better adaptation vs wild types [note, the cardiac function of wild types and K225A mutants at the baseline were indistinguishable ( fig. S4) ]. Therefore, inhibition of nuclear GAPDH cascade could ameliorate pathological hypertrophic remodeling consistently by pharmacological or by molecular intervention.
In the present study, we demonstrate a pivotal role for the nuclear GAPDH cascade in cardiac hypertrophy in response to pathological stress in vitro and in vivo. We propose that GAPDH may be a key homeostatic mediator in living organisms, given its robust expression in many tissues/organs. Interestingly, the molecular mechanism elicited by nuclear translocation of GAPDH in the heart is distinct from the cascades reported in the brain, implying the general and tissue/context-specific roles of GAPDH in stress response. It would be very interesting to identify the roles for nuclear GAPDH pathway in other organs and under diverse stress situations.
Our novel compound that specifically and potently blocks the nuclear GAPDH cascade, not only provides a potent means to determine these processes, but also open a window for potential therapeutic avenue. Since this cascade is likely to be involved in a variety of pathological conditions in which organ homeostasis is disturbed, it may have broad clinical applicability. Cardiac function of wild types (WT) and K225A mutants at the baseline, assessed by echocardiographic measures of FS, were indistinguishable. Table S1. In vitro screening for off-target activities of RR compound RR showed no significant interaction with primary targets of receptors, transporters, and enzymes in the Eurofins Panlabs Inc screen at the concentration of 1 µM, which is 1,000 fold high in comparison to that at which GAPDH-Siah1 binding was inhibited.
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